Differential Expression of AP-1 Transcription Factors in Human Prostate LNCaP and PC-3 Cells: Role of Fra-1 in Transition to CRPC Status

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2017 Apr 8

PMID 28386843

Citations 9

Authors

K Kavya

M Naveen Kumar

Rajeshwari H Patil

Shubha M Hegde

K M Kiran Kumar

Rashmi Nagesh

R L Babu

Govindarajan T Ramesh

S Chidananda Sharma

Affiliations

Soon will be listed here.

Abstract

Androgen receptor (AR) signaling axis plays a vital role in the development of prostate and critical in the progression of prostate cancer. Androgen withdrawal initially regresses tumors but eventually develops into aggressive castration-resistant prostate cancer (CRPC). Activator Protein-1 (AP-1) transcription factors are most likely to be associated with malignant transformation in prostate cancer. Hence, to determine the implication of AR and AP-1 in promoting the transition of prostate cancer to the androgen-independent state, we used AR-positive LNCaP and AR-negative PC-3 cells as an in vitro model system. The effect of dihydrotestosterone or anti-androgen bicalutamide on the cell proliferation and viability was assessed by MTT assay. Expression studies on AR, marker genes-PSA, TMPRSS2, and different AP-1 factors were analyzed by semi-quantitative RT-PCR and expressions of AR and Fra-1 proteins were analyzed by Western blotting. Dihydrotestosterone induced the cell proliferation in LNCaP with no effect on PC-3 cells. Bicalutamide decreased the viability of both LNCaP and PC-3 cells. Dihydrotestosterone induced the expression of AR, PSA, c-Jun, and Fra-1 in LNCaP cells, and it was c-Jun and c-Fos in case of PC-3 cells, while bicalutamide decreased their expression. In addition, constitutive activation and non-regulation of Fra-1 by bicalutamide in PC-3 cells suggested that Fra-1, probably a key component, involved in transition of aggressive androgen-independent PC-3 cells with poor prognosis.

Citing Articles

Transcription Factors in Prostate Cancer: Insights for Disease Development and Diagnostic and Therapeutic Approaches.

Silva K, Tambwe N, Mahfouz D, Wium M, Cacciatore S, Paccez J Genes (Basel). 2024; 15(4).

PMID: 38674385 PMC: 11050257. DOI: 10.3390/genes15040450.

Role of the Dietary Phytochemical Curcumin in Targeting Cancer Cell Signalling Pathways.

Mishra A, Swetanshu , Singh P, Yadav S, Nigam M, Seidel V Plants (Basel). 2023; 12(9).

PMID: 37176840 PMC: 10180989. DOI: 10.3390/plants12091782.

Strategies to target the cancer driver MYC in tumor cells.

Weber L, Hartl M Front Oncol. 2023; 13:1142111.

PMID: 36969025 PMC: 10032378. DOI: 10.3389/fonc.2023.1142111.

Nobiletin, a citrus polymethoxyflavone, enhances the effects of bicalutamide on prostate cancer cells down regulation of NF-κB, STAT3, and ERK activation.

Ma Y, Ren X, Patel N, Xu X, Wu P, Liu W RSC Adv. 2022; 10(17):10254-10262.

PMID: 35498570 PMC: 9050343. DOI: 10.1039/c9ra10020b.

The Role of Curcumin in Cancer Treatment.

Zoi V, Galani V, Lianos G, Voulgaris S, Kyritsis A, Alexiou G Biomedicines. 2021; 9(9).

PMID: 34572272 PMC: 8464730. DOI: 10.3390/biomedicines9091086.

References

Pfarr C, Mechta F, Spyrou G, lAllemand D, Carillo S, Yaniv M . Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras. Cell. 1994; 76(4):747-60. DOI: 10.1016/0092-8674(94)90513-4. View

Li L, Liu L, Rao J, Esmaili A, Strauch E, Bass B . JunD stabilization results in inhibition of normal intestinal epithelial cell growth through P21 after polyamine depletion. Gastroenterology. 2002; 123(3):764-79. DOI: 10.1053/gast.2002.35386. View

Andreucci J, Grant D, Cox D, Tomc L, Prywes R, Goldhamer D . Composition and function of AP-1 transcription complexes during muscle cell differentiation. J Biol Chem. 2002; 277(19):16426-32. DOI: 10.1074/jbc.M110891200. View

Floyd Jr M, Floyd Jr M, Teahan S, Fitzpatrick J, Watson R . Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines. Prostate Cancer Prostatic Dis. 2008; 12(1):25-33. DOI: 10.1038/pcan.2008.23. View

Kaminska B, Pyrzynska B, Ciechomska I, Wisniewska M . Modulation of the composition of AP-1 complex and its impact on transcriptional activity. Acta Neurobiol Exp (Wars). 2000; 60(3):395-402. DOI: 10.55782/ane-2000-1358. View

Vicentini C, Festuccia C, Angelucci A, Gravina G, Muzi P, Eleuterio E . Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures. Anticancer Res. 2003; 22(5):2917-22. View

Chen S, Cai C, Fisher C, Zheng Z, Omwancha J, Hsieh C . c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene. 2006; 25(54):7212-23. DOI: 10.1038/sj.onc.1209705. View

Lee E, Zhan P, Schallhom R, Packman K, Tenniswood M . Antiandrogen-induced cell death in LNCaP human prostate cancer cells. Cell Death Differ. 2003; 10(7):761-71. DOI: 10.1038/sj.cdd.4401228. View

Burlacu A . Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med. 2003; 7(3):249-57. PMC: 6741335. DOI: 10.1111/j.1582-4934.2003.tb00225.x. View

10.

Vaarala M, Porvari K, KYLLONEN A, Lukkarinen O, Vihko P . The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer. 2001; 94(5):705-10. DOI: 10.1002/ijc.1526. View

11.

Shaulian E, Karin M . AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002; 4(5):E131-6. DOI: 10.1038/ncb0502-e131. View

12.

Li J, Xiang S, Zhang Q, Wu J, Tang Q, Zhou J . Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C. J Exp Clin Cancer Res. 2015; 34:46. PMC: 4446835. DOI: 10.1186/s13046-015-0168-z. View

13.

Gunthert A, Grundker C, Hollmann K, Emons G . Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells. Biochem Biophys Res Commun. 2002; 294(1):11-5. DOI: 10.1016/S0006-291X(02)00427-8. View

14.

Chinenov Y, Kerppola T . Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene. 2001; 20(19):2438-52. DOI: 10.1038/sj.onc.1204385. View

15.

Eferl R, Wagner E . AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003; 3(11):859-68. DOI: 10.1038/nrc1209. View

16.

Sharma S, Clemens J, Pisarska M, Richards J . Expression and function of estrogen receptor subtypes in granulosa cells: regulation by estradiol and forskolin. Endocrinology. 1999; 140(9):4320-34. DOI: 10.1210/endo.140.9.6965. View

17.

Masiello D, Cheng S, Bubley G, Lu M, Balk S . Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem. 2002; 277(29):26321-6. DOI: 10.1074/jbc.M203310200. View

18.

Attar R, Takimoto C, Gottardis M . Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res. 2009; 15(10):3251-5. DOI: 10.1158/1078-0432.CCR-08-1171. View

19.

Cunha G, Donjacour A, Cooke P, Mee S, Bigsby R, Higgins S . The endocrinology and developmental biology of the prostate. Endocr Rev. 1987; 8(3):338-62. DOI: 10.1210/edrv-8-3-338. View

20.

Babu R, Kumar M, Patil R, Devaraju K, Ramesh G, Sharma S . Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells: role of c-Jun, c-Fos, and Fra-1 in cell cycle regulation. Mol Cell Biochem. 2013; 380(1-2):143-51. DOI: 10.1007/s11010-013-1667-x. View